Servier România

Servier România company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are an international pharmaceutical company governed by a non-profit foundation, with our headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.615 billion euros in 2018, we employ 22.000 people worldwide. Entirely independent, we reinvest 23% of our turnover (excluding generic drugs) in research and development and use all our profits for development. Corporate growth is driven by our constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, cancer and diabetes, as well as by our activities in high-quality generic drugs. Currently, we have 30 drug candidates including 16 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise. To report a suspected adverse event with a Servier drug, please visit www.servier.ro

Company Details

Employees
66
Founded
-
Address
Strada Tipografilor, Nr. 11-15, S-Park,corp A1,et. 3,romania
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Sectorul 1, Bucureşti
Looking for a particular Servier România employee's phone or email?

Servier România Questions

News

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate - Fierce Biotech

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate Fierce Biotech

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - Servier

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US - Fierce Biotech

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US Fierce Biotech

Integrated annual report 2023/2024 - Servier

Integrated annual report 2023/2024 Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition - Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition Servier

Servier and Google Cloud Expand Partnership on using data and AI - Servier

Servier and Google Cloud Expand Partnership on using data and AI Servier

Servier tackles environmental challenges, transforming itself for a more sustainable future! - Servier

Servier tackles environmental challenges, transforming itself for a more sustainable future! Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 - Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 Servier

Learn more about our development portfolio - Servier

Learn more about our development portfolio Servier

Third-Party Sponsored Studies - Servier

Third-Party Sponsored Studies Servier

See our bases throughout the world - Servier

See our bases throughout the world Servier

The Group in figures - Servier

The Group in figures Servier

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences - Servier

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences Servier

Our commitment to neurology - Servier

Our commitment to neurology Servier

Our ambition for 2030 - Servier

Our ambition for 2030 Servier

Servier Executive Committee appointments - Servier

Servier Executive Committee appointments Servier

7 start-ups hosted - Servier

7 start-ups hosted Servier

Schema describing Servier’s governance structure - Servier

Schema describing Servier’s governance structure Servier

Servier x Owkin: AI-driven precision therapeutics - Servier

Servier x Owkin: AI-driven precision therapeutics Servier

Our commitment to oncology - Servier

Our commitment to oncology Servier

Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma - PR Newswire

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma PR Newswire

Drugmaker Servier loses EU court fight over pay-for-delay deals - Reuters

Drugmaker Servier loses EU court fight over pay-for-delay deals Reuters

Servier is boosting its digital transformation with Google Cloud! - Servier

Servier is boosting its digital transformation with Google Cloud! Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN - Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN Servier

Servier reveals a new visual identity - Servier

Servier reveals a new visual identity Servier

Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA - BioSpace

Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA BioSpace

The Research and Development Institute in Paris-Saclay - Servier

The Research and Development Institute in Paris-Saclay Servier

Servier Buys Fragile X Syndrome Candidate for up to $450M - Genetic Engineering and Biotechnology News

Servier Buys Fragile X Syndrome Candidate for up to $450M Genetic Engineering and Biotechnology News

PRISM BioLab, a new partner for Servier in immuno-oncology - Servier

PRISM BioLab, a new partner for Servier in immuno-oncology Servier

Fostering a healthy environment - Servier

Fostering a healthy environment Servier

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect - Fierce Biotech

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect Fierce Biotech

Servier leverages Aitia's digital twins to drive glioma drug development - FirstWord Pharma

Servier leverages Aitia's digital twins to drive glioma drug development FirstWord Pharma

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M - Fierce Pharma

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M Fierce Pharma

Servier completes acquisition of Agios Pharmaceuticals’ oncology business - Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

Servier takes aim at US oncology market, doubling R&D lab space in Boston - Fierce Biotech

Servier takes aim at US oncology market, doubling R&D lab space in Boston Fierce Biotech

Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor - Fierce Pharma

Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor Fierce Pharma

Servier severs CAR-T collab with Allogene, handing back rights outside the US to 3 candidates - Fierce Biotech

Servier severs CAR-T collab with Allogene, handing back rights outside the US to 3 candidates Fierce Biotech

All our latest news - Servier

All our latest news Servier

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says - Fierce Pharma

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer - MedCity News

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer MedCity News

Servier found guilty of fraud, manslaughter in long-running case over deadly weight-loss pill - Fierce Pharma

Servier found guilty of fraud, manslaughter in long-running case over deadly weight-loss pill Fierce Pharma

Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' - Fierce Biotech

Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' Fierce Biotech

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) - The New York Times

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) The New York Times

Tutorial Videos - Servier Medical Art

Tutorial Videos Servier Medical Art

Servier v. Commission (Case T 691/14): 5 crucial points of the second “pay-for-delay” decision of the EU General Court - Wolters Kluwer

Servier v. Commission (Case T 691/14): 5 crucial points of the second “pay-for-delay” decision of the EU General Court Wolters Kluwer

Receptors and Channels - Servier Medical Art

Receptors and Channels Servier Medical Art

French drugmaker Servier ordered to pay $471m over Mediator scandal - RFI

French drugmaker Servier ordered to pay $471m over Mediator scandal RFI

Top Servier România Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant